ZYNE News and Press, Zynerba Pharmaceuticals Inc. From 08/24/23

NEW YORK, NY / ACCESSWIRE / August 24, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Earthstone Energy, Inc. (NYSE:ESTE)...

NEW YORK, NY / ACCESSWIRE / August 18, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: New Relic, Inc. (NYSE:NEWR)'s sal...

NEW YORK, NY / ACCESSWIRE / August 15, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Decibel Therapeutics, Inc. (NASDAQ:...

2023-08-14 08:01:42 ET More on Zynerba Zynerba says not holding cash deposits or securities at Silicon Valley Bank Zynerba delaying release of late-stage top-line results for Fragile X syndrome candidate Zynerba rises on orphan drug status for cannabidiol Zygel for 2...

HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC. Acquisition expands pipeline and diversifies portfolio to drive long-term growth Innovative potential new therapeutic option for rare/orphan neuropsychiatric disorders with high unmet medical needs Lead asset in pivota...

DEVON, Pa., July 25, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) (the “Company”), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the new date for the adjourned...

Annual Meeting Reconvened and Adjourned Without Conducting Business Meeting to Reconvene on July 27, 2023 at 9:00 am EDT DEVON, Pa., June 28, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) (the “Company”), the leader in innovative pharmaceuticall...

DEVON, Pa., June 20, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of ...

Meeting adjourned with respect to Proposal 2, Reverse Stock Split; Company encourages additional stockholders of record to vote before reconvened meeting on June 28, 2023 All other proposals approved DEVON, Pa., June 13, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasd...

2023-05-24 13:33:04 ET In its preliminary annual 2023 Russell indexes reconstitution, a total of 164 companies will be added and 319 deleted from the Russell microcap index. Following notable healthcare companies will be added and deleted from Russell microcap index: Notable additio...